Journal of Clinical Oncology
Articles in this Issue
Clinical and radiographic trends in patients with renal angiomyolipomas (AML).
458 Background: Renal angiomyolipoma (AML) is a common benign solid tumor of the kidney, typically found incidentally through imaging. These tumors can al...
A retrospective real-world study of disitamab vedotin combined with tislelizumab versus chemotherapy in patients with previously untreated metastatic urothelial carcinoma.
733 Background: Eligible patients with metastatic urothelial carcinoma (mUC) typically receive platinum-based chemotherapy as first-line therapy. Recently...
Impact of relative dose intensity on efficacy of enfortumab vedotin monotherapy in platinum and ICI resistant metastatic urothelial carcinoma: A multi-institutional real-world analysis.
728 Background: The treatment paradigm for metastatic or locally advanced urothelial carcinoma (mUC) has shifted towards combination therapies with Enfort...
Association of statin use with overall survival and cardiac adverse events in patients with advanced prostate cancer treated with apalutamide: A pooled analysis of TITAN and SPARTAN.
137 Background: The impact of statins on overall survival (OS) in patients (pts) with advanced prostate cancer is not fully understood. We performed a poo...
Association between abnormal IMDC laboratory criteria after surgery and cancer-specific and overall survival in non-metastatic renal cell carcinoma: Potential biomarkers for adjuvant therapy patient selection.
567 Background: The International Metastatic RCC Database Consortium (IMDC) criteria are widely used for risk stratification in metastatic renal cell carc...
Apatinib monotherapy for pretreated advanced squamous cell carcinoma of the penis: A phase II trial.
8 Background: Treatment options for patients with advanced penile squamous cell carcinoma who have disease progression on...
A phase 2 trial of neoadjuvant futibatinib plus durvalumab for cisplatin-ineligible patients with <i>FGFR</i> overexpressing muscle-invasive bladder cancer.
TPS899 Background: There is an unmet need to develop neoadjuvant therapies for cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MI...
Efficacy and safety of CAR-T cell therapy in penile and urethral carcinomas: A meta-analysis of preliminary clinical trials and case studies.
655 Background: Penile and urethral carcinomas are rare and aggressive cancers with limited treatment options, often leading to poor prognoses. Chimeric A...
Inclusion of patients with reduced performance status (ECOG 2 or higher) in FDA registrational trials for renal cell carcinoma (RCC).
453 Background: Clinical trials often use performance status indicators to include only those participants with good baseline functional status. The Easte...
Patterns of hospital admissions and readmissions due to immune-related adverse events in patients with genitourinary cancers.
462 Background: Immune checkpoint therapies (ICTs) improve survival in patients with genitourinary (GU) cancers, specifically renal cell carcinoma (RCC) a...
Systemic therapies in renal cell carcinoma with brain metastases: A comparative meta-analysis of immunotherapy and tyrosine kinase inhibitors.
559 Background: Renal cell carcinoma (RCC) with brain metastases presents a clinical challenge. Management remains unclear, as systemic therapy data are l...
Preliminary efficacy and safety of disitamab vedotin (DV) combined with bacillus Calmette-Guérin (BCG) in the treatment of high-risk non-muscle invasive bladder cancer with HER2 expression: A prospective, open label, single-center study.
775 Background: Current treatment for high-risk non-muscle invasive bladder cancer (HR-NMIBC) involves Bacillus Calmette-Guérin (BCG) therapy, or radical...
Evaluating clinical tools to monitor cardiovascular (CV) risk in men with localized high-risk or locally advanced prostate cancer (LHRPC) treated with hormone therapy (HT).
116 Background: Androgen deprivation therapy (ADT) and androgen receptor signaling inhibitors (ARSIs) indirectly increase CV risk. There are no risk estim...
A phase 1b, open-label, multicenter study of xaluritamig in patients with newly diagnosed localized intermediate- or high-risk prostate cancer in the neoadjuvant setting.
TPS434 Background: There are currently no standard neoadjuvant treatments for patients with localized prostate cancer despite improved outcomes with neoad...
Phase 1/2 INTerpath-005 study: V940 (mRNA-4157) plus pembrolizumab with or without enfortumab vedotin (EV) for resected high-risk muscle-invasive urothelial carcinoma (MIUC).
TPS893 Background: It is hypothesized that V940 (mRNA-4157), an individualized neoantigen therapy consisting of an mRNA en...
Analysis of gut microbiota profiles in patients with prostate cancer: The PROMISE-JAPAN study.
212 Background: Prostate cancer (PCa) is clinically associated with dietary habits such as high-fat diets. The gut microbiota is strongly influenced by di...
RadOnc-GPT (gpt-4o) versus human data extraction for prostate cancer clinical research.
425 Background: Prostate cancer (PC) ranks among the most prevalent cancers in men, with incidence rising due to factors like aging populations and enhanc...
Clinically advanced prostate cancer (CAPC) in extremely young men: A genomic landscape study.
210 Background: CAPC arising in young patients is a challenging disease with significant need for improvements in systemic therapies, especially for patie...
The Oncopig bladder cancer model, an innovative large animal platform for evaluating treatment effects.
857 Background: Bladder cancer carries a high recurrence rate despite availability of several treatment options including surgery, chemotherapy, radiation...
Association of a novel AI-based digital pathology (CHAI) biomarker with progression free survival (PFS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC).
204 Background: In mHSPC, no baseline biomarker reliably predicts progression-free survival (PFS). Identifying pts unlikely to benefit from current therap...
Association between site of metastases and survival stratification of the IMDC classification in metastatic renal cell carcinoma (mRCC).
566 Background: The IMDC risk model is pivotal for prognostic stratification of mRCC, dividing patients into favorable (FAV), intermediate (INT) and poor-...
Impact of geographic and demographic characteristics on treatment with Lu-PSMA for metastatic castrate-resistant prostate cancer (mCRPC).
153 Background: Metastatic castration-resistant prostate cancer (mCRPC) remains an incurable and fatal disease. Administration of Lu-PSMA demonstrates imp...
Current impact of ureteral carcinoma amongst racial minorities: Analysis of the National Cancer Database.
675 Background: Upper tract cancer is a relatively uncommon type of genitourinary cancer. Lower socioeconomic status and racial disparities have long been...
Risk factors of complications after inguinal lymph node dissection in patients with penile cancer.
6 Background: Inguinal lymph node dissection (ILND) is a crucial step in the management of patients with penile cancer, particularly for those with lymph...
Evaluating the survival benefits of adjuvant immunotherapy in muscle-invasive urothelial carcinoma: A real-world experience.
750 Background: Despite current guidelines recommendations to administer adjuvant nivolumab following radical cystectomy (RC) in patients with adverse pat...